Clinical trials: completed, sponsored by ModernaTX, Inc.
Influenza, SARS-CoV-2
A Clinical Study to Investigate the Safety and Immunogenicity in Relation to Product Attributes of mRNA-1083 (Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2] and Influenza Vaccine)
The purpose of this study is to evaluate the safety, reactogenicity, and immunogenicity in relation to the product attributes of mRNA-1083 vaccine when administered as a single intramuscular (IM) injection in adults ≥50 to <65…
- Trial name
- NCT06508320
- Testing
- mRNA-1083
- Where
- 17 sites in United States, Canada
- Volunteers
- 931 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Respiratory Syncytial Virus
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥60 Years of Age
The main purpose of Part A of this study is to evaluate the safety and tolerability of mRNA-1345 vaccine and to demonstrate the efficacy of a single dose of mRNA-1345 vaccine in the prevention of a first episode of RSV-associated…
- Trial name
- NCT05127434
- Testing
- mRNA-1345
- Where
- 269 sites in United States, Argentina and 21 more
- Volunteers
- 36,814 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Seasonal Influenza
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age
The primary objectives of this study are to evaluate the safety and reactogenicity of mRNA-1010, and to evaluate relative vaccine efficacy (rVE) of mRNA-1010 versus an active comparator against reverse transcription polymerase…
- Trial name
- NCT06602024
- Testing
- mRNA-1010, Fluarix®, Influsplit® Tetra
- Where
- 301 sites in United States, Belgium and 9 more
- Volunteers
- 40,805 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Respiratory Syncytial Virus
A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus
Part A: The purpose is to evaluate the safety, reactogenicity, and immunogenicity of mRNA-1345 in children aged 2 to <5 years (Cohort 1) and in children at high risk of respiratory syncytial virus (RSV) disease 5 to <18 years of…
- Trial name
- NCT06097299
- Testing
- mRNA-1345
- Where
- 50 sites in United States, Panama
- Volunteers
- 349 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Lyme Disease
A Study to Evaluate the Safety and Immunogenicity of mRNA-1975 and mRNA-1982 Against Lyme Disease in Participants 18 Through 70 Years of Age
The purpose of this study is to evaluate the safety and immunogenicity in parallel of heptavalent mRNA-1975 and monovalent mRNA-1982 against Lyme disease in healthy adult participants.
- Trial name
- NCT05975099
- Testing
- mRNA-1975, mRNA-1982
- Where
- 20 sites in United States
- Volunteers
- 807 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Genital Herpes
A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes
The purpose of this study is to generate safety and immunogenicity data and establish a proof-of-concept of clinical benefit of the mRNA-1608 vaccine candidate.
- Trial name
- NCT06033261
- Testing
- mRNA-1608, BEXSERO
- Where
- 23 sites in United States
- Volunteers
- 303 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Cytomegalovirus Infection
Dose-Finding Trial to Evaluate the Safety and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647 in Healthy Adults
This clinical study will assess the safety and immunogenicity of 3 dose levels of mRNA-1647 cytomegalovirus vaccine in CMV-seronegative and CMV-seropositive healthy adults 18-40 years of age.
- Trial name
- NCT04232280
- Testing
- mRNA-1647
- Where
- 9 sites in United States
- Volunteers
- 315 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
COVID-19
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ≥12 Years of Age to Prevent COVID-19
The purpose of this study (Part 1 and Part 2) is to evaluate the relative vaccine efficacy (rVE), safety, reactogenicity, and immunogenicity of mRNA-1283.222 versus mRNA-1273.222 (Part 1) and mRNA-1283.815 versus mRNA-1273.815…
- Trial name
- NextCOVE (NCT05815498)
- Testing
- mRNA-1283.222, mRNA-1273.222, mRNA-1283.815
- Where
- 230 sites in United States, Canada and 2 more
- Volunteers
- 13,553 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Healthy Volunteers
A Study to Investigate Cardiac Troponin Levels After mRNA-1273.712 Vaccine in Participants 12 Through 30 Years of Age
The primary objective of this study is to assess cardiac troponin I (cTnI) values in participants who received mRNA-1273.712 or placebo.
- Trial name
- NCT06634797
- Testing
- mRNA-1273.712
- Where
- 24 sites in United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Respiratory Syncytial Virus
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥50 Years of Age
The main purposes of Part A of this study are to evaluate the safety, tolerability, and immunogenicity of mRNA-1345 coadministered with a seasonal influenza vaccine (Afluria® Quadrivalent); to evaluate the impact of…
- Trial name
- RSVictory (NCT05330975)
- Testing
- mRNA-1345, Afluria® Quadrivalent, mRNA-1273.214
- Where
- 62 sites in United States
- Volunteers
- 3,317 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
SARS-CoV-2, Influenza
A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults
The study is divided into 2 parts: Part 1 and Part 2. The purpose of Part 1 of this study is to generate sufficient safety, reactogenicity, and immunogenicity data to enable selection of an mRNA-1083 vaccine composition and dose…
- Trial name
- NCT05827926
- Testing
- Influenza Vaccine 1, mRNA-1083.1, mRNA-1083.2
- Where
- 69 sites in United States
- Volunteers
- 1,758 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Zika Virus
A Study of Zika Vaccine mRNA-1893 in Adult Participants Living in Endemic and Non-Endemic Flavivirus Areas
This clinical study will evaluate the safety, tolerability, and reactogenicity of 2 dose levels of messenger RNA (mRNA)-1893 Zika vaccine in comparison to a placebo control in healthy participants who are flavivirus-seronegative…
- Trial name
- NCT04917861
- Testing
- mRNA-1893
- Where
- 11 sites in United States, Puerto Rico
- Volunteers
- 808 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
SARS-CoV-2
A Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 Vaccine in Adolescents 12 to <18 Years Old to Prevent COVID-19
The mRNA-1273 vaccine is being developed to prevent COVID-19, the disease resulting from Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) infection.
- Trial name
- TeenCove (NCT04649151)
- Testing
- mRNA-1273, mRNA-1273.222
- Where
- 53 sites in United States, Dominican Republic
- Volunteers
- 4,328 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Respiratory Syncytial Virus
A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ≥65 Years of Age
The main purpose of this study is to evaluate the safety and immunogenicity of mRNA-1345 RSV vaccine when coadministered with a high dose (HD) quadrivalent seasonal influenza vaccine (Fluzone HD) in adults ≥65 years of age.
- Trial name
- NCT06060457
- Testing
- mRNA-1345, Fluzone HD
- Where
- 34 sites in United States
- Volunteers
- 1,900 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
SARS-CoV-2
A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Vaccine Boosters
The main goal of Part A of this study is to assess the safety, reactogenicity, and immunogenicity of the study vaccine candidates.
- Trial name
- NCT05137236
- Testing
- mRNA-1283, mRNA-1283.211, mRNA-1273
- Where
- 17 sites in United States
- Volunteers
- 540 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Seasonal Influenza
Study of mRNA-1010 Seasonal Influenza Vaccine in Adults
This study includes 3 parts: Parts A, B, and C. The purpose of this study is to evaluate the immunogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults.
- Trial name
- IGNITE P303 (NCT05827978)
- Testing
- mRNA-1010, Licensed Quadrivalent Inactivated Seasonal Influenza Vaccine
- Where
- 103 sites in United States
- Volunteers
- 8,411 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
SARS-CoV-2, Influenza
A Study of mRNA-1083 (SARS-CoV-2 and Influenza) Vaccine in Healthy Adult Participants, ≥50 Years of Age
The purpose of this study is to evaluate the immunogenicity, safety, and reactogenicity of mRNA-1083 as compared with active control, co-administered licensed influenza and severe acute respiratory syndrome coronavirus 2 (SARS…
- Trial name
- NCT06097273
- Testing
- mRNA-1083, Influenza Vaccine, COVID-19 Vaccine
- Where
- 146 sites in United States
- Volunteers
- 8,061 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
SARS-CoV-2
A Study to Evaluate Safety and Effectiveness of mRNA-1273 COVID-19 Vaccine in Healthy Children Between 6 Months of Age and Less Than 12 Years of Age
The primary goal for this study is to evaluate up to 3 dose levels of mRNA-1273 vaccine given to healthy children as intramuscular (IM) injection in 2 doses (in Parts 1 and 2) and 3 doses (in Part 3), and a third dose or an…
- Trial name
- NCT04796896
- Testing
- mRNA-1273, mRNA-1273.214
- Where
- 91 sites in United States, Canada
- Volunteers
- 11,942 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
SARS-CoV-2
A Study of an Investigational mRNA-1273.815 COVID-19 Vaccine in Previously Vaccinated Adults
To evaluate immune responses of an Investigational mRNA-1273.815 vaccine against the Omicron subvariant strain (XBB.1.5) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
- Trial name
- NCT06354998
- Testing
- Investigational mRNA-1273.815, Licensed Spikevax Vaccine
- Where
- 7 sites in Australia
- Volunteers
- 217 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
SARS-CoV-2
A Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 (COVID-19) Variants
This is a study to evaluate the immunogenicity, safety, and reactogenicity of mRNA-1273.211, mRNA-1273, mRNA-1273.617.2, mRNA-1273.213, mRNA-1273.529, mRNA-1273.214, mRNA-1273.222, mRNA-1273.815, and mRNA-1273.231 administered as…
- Trial name
- NCT04927065
- Testing
- mRNA-1273.211, mRNA-1273, mRNA-1273.617.2
- Where
- 23 sites in United States
- Volunteers
- 5,161 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.